Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;28(1):84-91.
doi: 10.1177/15910199211015038. Epub 2021 May 4.

Glycoprotein IIb/IIIa inhibitors for the neurointerventionalist

Davide Simonato  1   2 , Robin J Borchert  3 , Marc-Antoine Labeyrie  4 , Maurizio Fuschi  1 , Lucie Thibault  5 , Hans Henkes  6 , David Fiorella  7 , Benjamin Yq Tan  8 , Leonard Ll Yeo  8 , Hegoda Ld Makalanda  9 , Ken Wong  9 , Pervinder Bhogal  9
Affiliations
Review

Glycoprotein IIb/IIIa inhibitors for the neurointerventionalist

Davide Simonato et al. Interv Neuroradiol. 2022 Feb.

Abstract

Antiplatelet therapies are commonly used in neurointerventional procedures. However, specific guidelines for their use in these settings is lacking and it can often be difficult to balance the potential risks and benefits of these medications. Considering the continued growth and adoption of neurointerventional procedures, it is crucial to understand the properties of these agents in order to use them safely. Large-scale clinical trials are still needed to clarify many of these aspects for this emerging field. However, the existing literature already provides insight into which antiplatelet drugs are of benefit to the neurointerventionalist as well as their associated risks of ischemic and hemorrhagic complications. Hence, this review focuses on the applications of GPIIb/IIIA inhibitors to neurointerventional procedures.

Keywords: Platelets; aneurysm; hemorrhage; stroke; thrombectomy.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Platelet activation pathways targeted by antiplatelet drugs including GP IIb/IIIa, P2Y12 and COX-1 inhibitors.
See this image and copyright information in PMC

References

    1. Borchert B, Simonato D, Hickman CR, et al. P2Y12 inhibitors for the neurointerventionalist. Under Review 2021.
    1. Murugappan S, Shankar H, Kunapuli SP. Platelet receptors for adenine nucleotides and thromboxane A2. Semin Thromb Hemost 2004; 30: 411–418. - PubMed
    1. Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000; 139: S38–S45. - PubMed
    1. Dornbos D, Katz JS, Youssef P, et al. Glycoprotein IIb/IIIa inhibitors in prevention and rescue treatment of thromboembolic complications during endovascular embolization of intracranial aneurysms. Neurosurgery 2018; 82: 268–277. - PubMed
    1. Bruening R, Mueller-Schunk S, Morhard D, et al. Intraprocedural thrombus formation during coil placement in ruptured intracranial aneurysms: treatment with systemic application of the glycoprotein IIb/IIIa antagonist tirofiban. Ajnr Am J Neuroradiol 2006; 27: 1326–1331. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources